Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Reviews
Nature Immunology
Nature Cell Biology
Nature Genetics
news@nature.com
Nature Conferences
Dissect Medicine
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Article
Nature Medicine  3, 1354 - 1361 (1997)
doi:10.1038/nm1297-1354

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells

Zvi Ram1, 6, Kenneth W. Culver2, Eric M. Oshiro1, John J. Viola1, Hetty L. DeVroom1, Edward Otto3, Zhifeng Long3, Yawen Chiang3, Gerard J. McGarrity3, Linda M. Muul4, David Katz5, R. Michael Blaese4 & Edward H. Oldfield1, 7

  1Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke (NINDS), 10/5D37, 10 Center Drive, Bethesda, Maryland 20892, USA

  2Metabolism Branch, National Cancer Institute, 10/5D45, 10 Center Drive, Bethesda, Maryland 20892, USA

  3Genetic Therapy, Inc., 938 Clopper Road, Gaithersburg, Maryland, USA

  4Clinical Gene Therapy Branch, National Center for Human Genome Research, 10/10C103, 10 Center Drive, Bethesda, Maryland 20892, USA

  5Office of the Clinical Director and Laboratory of Pathology, NINDS, 10/5N220, 10 Center Drive, Bethesda, Maryland 20892, USA

  6Department of Neurosurgery, The Chaim Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel Hashomer 52621, Israel

  7Correspondence should be addressed to E.H.O.

Intratumoral implantation of murine cells modified to produce retroviral vectors containing the herpes simplex virus-thymidine kinase (HSV-TK) gene induces regression of experimental brain tumors in rodents after ganciclovir (GCV) administration. We evaluated this approach in 15 patients with progressive growth of recurrent malignant brain tumors. Antitumor activity was detected in five of the smaller tumors (1.4 plusminus 0.5 ml). In situ hybridization for HSV-TK demonstrated survival of vector-producing cells (VPCs) at 7 days but indicated limited gene transfer to tumors, suggesting that indirect, "bystander," mechanisms provide local antitumor activity in human tumors. However, the response of only very small tumors in which a high density of vector-producing cells had been placed suggests that techniques to improve delivery and distribution of the therapeutic gene will need to be developed if clinical utility is to be achieved with this approach.

REFERENCES
  1. Barba, D., Hardin, J., Ray, J. & Gage, F.H. Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79, 729−735 (1993).
  2. Culver, K.W. et al. In vivo gene transfer with retroviral vector-producing cells for treatment of experimental brain tumors. Science 256, 1550−1552 (1992).
  3. Ezzeddine, Z.D. et al. Selective killing of glioma Cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 3, 608−614 (1991).
  4. Caruso, M. et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA 90, 7024−7028 (1993).
  5. Moolten, F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276−5281 (1986).
  6. Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M. & Oldfield, E.H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83−88 (1993).
  7. Mann, R., Mulligan, R.C. & Baltimore, D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33, 153−159 (1983).
  8. Short, M.P. et al. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res. 27, 427−439 (1990).
  9. Burger, P. & Scheithauer, B. Tumors of the central nervous system. in Atlas of Tumor Pathology, Third Series, Fascicle 10, p. 59 (Armed Forces Institute of Pathology, Washington, D. C., 1994).
  10. Burger, P., Scheithauer, B. & Vogel, F. Surgical Pathology of the Nervous System and Its Coverings. (Churchill Livingstone, New York, 1991).
  11. Bi, W.L., Parysek, L.M., Warnick, R. & Stambrook, P.J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV Tk retroviral gene therapy. Hum. Gene Ther. 4, 725−731 (1993).
  12. Ishii, H. et al. Mechanism of "bystander effect" killing in the herpes simplex thymidine kinase gene therapy model of cancer. Gene Ther. 4, 244−251 (1997).
  13. Kato, K., Yoshida, J., Mizuno, M., Sugita, K. & Emi, N. Retroviral transfer of herpes simplex thymidine kinase into glioma Cells targeting of gancyclovir cytotoxic effect. Neurol. Med. Chir. (Tokyo) 34, 339−344 (1994).
  14. Wu, J., et al. Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 35, 1094−1102 (1994).
  15. Freeman, S.M., et al. The bystander effect: Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274−5283 (1993).
  16. Denekamp, J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Rad. 66, 181−196 (1993).
  17. Ram, Z., et al. The effect on tumoral vascufature and growth of thymidine kinase-transduced, ganciclovir-treated 9L gliomas in rats. J. Neurosurg. 81, 256−260 (1994).
  18. Barba, D., Hardin, J., Sadelain, M. & Gage, F.H. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91, 4348−4352 (1994).
  19. Moolten, F.L. & Wells, J.M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82, 297−300 (1990).
  20. Lyons, R. et al. An improved vector encoding the herpes simplex virus thymidine kinase gene increases antitumor efficacy in vivo. Cancer Gene Ther. 2, 273−280 (1995).
  21. Boviatsis, E. et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 15, 5745−5751 (1994).
  22. Perez-Cruet, M., et al. Adenovirus-mediated gene therapy of experimental gliomas. J. Neurosci. Res. 39, 506−511 (1994).
  23. Chen, S.H., Shine, H.D., Goodman, J.C., Grossman, R.G. & Woo, S.L. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91, 3054−3057 (1994).
  24. Oldfield, E.H., Ram, Z., Culver, K.W., DeVroom, H.L. & Blaese, R.M. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39−69 (1993).
  25. Haapala, D.K., Robey, W.G., Oroszlan, S.D. & Tsai, W.P. Isolation from cats of an endogenous type C virus with a novel envelope glycoprotein. J. Virol. 53, 827−833 (1985).
  26. Cairncross, G., et al. Chemotherapy for anaplastic oligodendroglioma. J. Clin. Oncol. 12, 2013−2021 (1994).
  27. Macdonald, D., Cascino, T., Schold, S. & Cairncross, J. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277−1280 (1990).
  28. Pantaleo, G. et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355−358 (1993).
  29. Hsu, S.M., Raine, L. & Fanger, H. A comparative study of the PAP method and avidin-biotin-complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am. J. Clin. Pathol. 75, 734−738 (1981).
 Top
 Top
Abstract
Previous | Next
Table of contents
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

Open Innovation Challenges

naturejobs

References
Export citation
Export references
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Medicine
ISSN: 1078-8956
EISSN: 1546-170X
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©1997 Nature Publishing Group | Privacy policy